BAJAJ BROKING
US FDA completed the pre-approval inspection at Aurobindo Pharma’s Eugia Steriles unit in Andhra Pradesh, issuing five procedural observations. The company will address them within the required timeframe. Meanwhile, Aurobindo Pharma share price closed at ₹1,162.55, down 0.64% on the BSE.
Aurobindo Pharma Ltd announced that the United States Food and Drug Administration (US FDA) has completed its pre-approval inspection (PAI) at Eugia Steriles Private Ltd, a subsidiary located in Parawada Mandal, Andhra Pradesh. The inspection, conducted between February 10 and February 18, 2025, concluded with five procedural observations. The company has assured that it will respond within the stipulated timeframe and will keep the stock exchanges informed of any further updates.
Also read: IREDA Subsidiary Gets Provisional Approval as Finance Company in GIFT City
The US FDA conducted a pre-approval inspection at Aurobindo Pharma’s Eugia Steriles unit.
The inspection took place from February 10 to February 18, 2025.
It concluded with five procedural observations, which the company will address.
The observations do not indicate critical compliance issues.
Aurobindo Pharma share price ended at ₹1,162.55, down 0.64% on the BSE.
Also read: RVNL Secures ₹554.47-Crore Contract for Bengaluru Suburban Rail Project
The US FDA’s inspection is a key regulatory step before approving a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA). The process ensures that the facility meets stringent manufacturing, processing, and quality control standards. Aurobindo Pharma has committed to addressing the procedural observations raised during the inspection.
Aurobindo Pharma’s Q3 FY25 performance reflected mixed results. The company’s net profit declined 9.7% year-on-year (YoY) to ₹845.8 crore, missing market expectations. However, revenue increased by 8.5% YoY, reaching ₹7,978.5 crore, driven by strong demand across key geographies. EBITDA stood at ₹1,627.7 crore, reflecting a slight decline of 1.5% compared to the previous year.
Despite steady revenue growth, the weaker-than-expected net profit led to a decline in Aurobindo Pharma share price, which closed at ₹1,162.55 on the BSE, down 0.64%.
Financial Metric | Q3 FY25 | Q3 FY24 | YoY Change |
Revenue | ₹7,978.5 crore | ₹7,353.8 crore | +8.5% |
Net Profit | ₹845.8 crore | ₹936 crore | -9.7% |
EBITDA | ₹1,627.7 crore | ₹1,601 crore | -1.5% |
Aurobindo Pharma Share Price | ₹1,162.55 (BSE) | NA | -0.64% |
Aurobindo Pharma’s latest inspection at Eugia Steriles highlights its ongoing regulatory compliance efforts. While the US FDA’s observations require attention, they do not indicate critical concerns. The company remains focused on addressing regulatory requirements while navigating market fluctuations. Despite a drop in Aurobindo Pharma share price, steady revenue growth indicates strong long-term potential in the pharmaceutical sector.
Also read: Mahindra Lifespace & Livingstone Infra Partner for ₹1,650 Cr Mahalaxmi Project
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading